Logo image of LVIDE.AS

LAVIDE HOLDING NV (LVIDE.AS) Stock Fundamental Analysis

Europe - AMS:LVIDE - NL0010545679 - Common Stock

0.53 EUR
-0.01 (-1.85%)
Last: 9/11/2025, 7:00:00 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to LVIDE. LVIDE was compared to 71 industry peers in the IT Services industry. LVIDE may be in some trouble as it scores bad on both profitability and health. LVIDE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

LVIDE had negative earnings in the past year.
LVIDE had negative earnings in each of the past 5 years.
LVIDE had a negative operating cash flow in each of the past 5 years.
LVIDE.AS Yearly Net Income VS EBIT VS OCF VS FCFLVIDE.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200K -400K -600K -800K -1M

1.2 Ratios

LVIDE has a worse Return On Assets (-1900.00%) than 94.37% of its industry peers.
Industry RankSector Rank
ROA -1900%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LVIDE.AS Yearly ROA, ROE, ROICLVIDE.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

LVIDE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LVIDE.AS Yearly Profit, Operating, Gross MarginsLVIDE.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

0

2. Health

2.1 Basic Checks

LVIDE has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for LVIDE has been increased compared to 5 years ago.
LVIDE has about the same debt/assets ratio as last year.
LVIDE.AS Yearly Shares OutstandingLVIDE.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
LVIDE.AS Yearly Total Debt VS Total AssetsLVIDE.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M

2.2 Solvency

LVIDE has an Altman-Z score of -10711.07. This is a bad value and indicates that LVIDE is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10711.07, LVIDE is doing worse than 87.32% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10711.07
ROIC/WACCN/A
WACCN/A
LVIDE.AS Yearly LT Debt VS Equity VS FCFLVIDE.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200K -200K 400K -400K 600K

2.3 Liquidity

LVIDE has a Current Ratio of 0.06. This is a bad value and indicates that LVIDE is not financially healthy enough and could expect problems in meeting its short term obligations.
LVIDE has a worse Current ratio (0.06) than 92.96% of its industry peers.
A Quick Ratio of 0.06 indicates that LVIDE may have some problems paying its short term obligations.
LVIDE has a Quick ratio of 0.06. This is amonst the worse of the industry: LVIDE underperforms 92.96% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
LVIDE.AS Yearly Current Assets VS Current LiabilitesLVIDE.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K

0

3. Growth

3.1 Past

The earnings per share for LVIDE have decreased by 0.00% in the last year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LVIDE.AS Yearly Revenue VS EstimatesLVIDE.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 100K 200K 300K

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LVIDE. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LVIDE.AS Price Earnings VS Forward Price EarningsLVIDE.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LVIDE.AS Per share dataLVIDE.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.02 -0.04 -0.06

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for LVIDE!.
Industry RankSector Rank
Dividend Yield N/A

LAVIDE HOLDING NV

AMS:LVIDE (9/11/2025, 7:00:00 PM)

0.53

-0.01 (-1.85%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners43.13%
Ins Owner ChangeN/A
Market Cap3.03M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.07
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1900%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -10711.07
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A